A carregar...

Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results

Targeting of HER2-positive tumors with trastuzumab has shown to improve survival in early stage and advanced breast cancer. The addition of pertuzumab, another anti-HER2 antibody, to trastuzumab-containing regimens has demonstrated a modest increase in disease-free survival in the adjuvant setting....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Ocaña, Alberto, Amir, Eitan, Pandiella, Atanasio
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2018
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6112749/
https://ncbi.nlm.nih.gov/pubmed/30159132
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25739
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!